Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Exosome liquid dressing
- Development stage
- Phase 1
- Lead developer
- Goodain (Beijing) Pharmaceutical Technology
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intrauterine Perfusion
01
Overview
Exosome liquid dressing, specifically GD007, is an exosome-based therapeutic derived from human induced pluripotent stem cells (iPSCs). Developed by Goodain (Beijing) Pharmaceutical Technology Co., Ltd., this product offers significant advantages over mesenchymal stem cell (MSC)-derived exosomes due to its clonal origin, ensuring superior batch-to-batch consistency and stability. It contains elevated levels of functional factors such as TGF-β (anti-inflammatory) and BDNF (neurotrophic), which contribute to its demonstrated biological effects including anti-apoptosis, inflammation suppression, angiogenesis promotion, fibrosis inhibition, and enhanced tissue repair potential. The drug is being investigated for the treatment of moderate-to-severe intrauterine adhesions (IUA) and has shown preclinical efficacy in models of neuroprotection, epilepsy, and stroke by modulating immune responses and promoting tissue regeneration.
- Other names
- Human iPSC-Exosome Liquid Dressing
02
Targets
BDNF (Brain-derived neurotrophic factor)IL-6 (Interleukin 6)TGFB (GARP–latent transforming growth factor beta 1 complex)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Exosome liquid dressing.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exosome liquid dressing.